TC

• Or maybe this excellent memoir by engineer and producer Tony Cohen, who died in 2017, will fling him into the spotlight.
• Cohen, who was mostly Melbourne-based, made an astonishing contribution to Australian recorded music in the 70s and 80s.
• The gist of the stories was pure, even if the dates might have needed a bit of research on Olson’s part.
• Read more:
  'A gentleman with the mad soul of an Irish convict poet': remembering Chris Bailey, and the blazing comet that was The Saints

‘Turn it up a bit more!’

• Working as an assistant, cleaning toilets and getting coffees, he was 15 and he had a job!
• In the first week he was paid $17 – “I was so young I spent it on lollies.
• I was up myself: a pot-smoking, acid-gobbling smart-arse who thought he knew it all.
• This time at Armstrong’s was informative, not just in learning what to do, but what not to do.
• And he talks a bit about Molly [Meldrum], which people will probably be surprised to read.” Cohen’s regard for Molly Meldrum is clear.

A strange, scrambled method

• He was daring to do different things, and there was a bit of "Fuck you!” to what the normal music benchmarks were.
• He was daring to do different things, and there was a bit of "Fuck you!” to what the normal music benchmarks were.
• He didn’t care that I wanted to tune my drums differently, it was all cool.
• Cohen wrote:
  I’ve got a strange, scrambled way of working.
• I know how to use most pieces of equipment, but I don’t necessarily know what they do or why they do it.
• I’ve got a strange, scrambled way of working.
• He was a master at both what not to do in the studio and what to do in the studio.

• BEIJING, June 15, 2023 /PRNewswire/ -- TuanChe Limited ("TuanChe" or the "Company") (NASDAQ: TC), a leading integrated automotive marketplace in China, today announced the appointment of Mr. Simon Li as chief financial officer, effective from June 15, 2023.
• Mr. Simon Li has extensive experience in investment and corporate finance.
• Mr. Wei Wen, Chairman and Chief Executive Officer of TuanChe, commented, "We welcome Mr. Simon Li to our company.
• Mr. Li possesses substantial experience in the financial arena and is well equipped to assume the role of chief financial officer.

• The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
• UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
• The oral presentation highlighted the following preclinical data:
  Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
• The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
  Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

• HK, "Akeso") announced today that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia (HeFH).
• Ebronucimab is jointly developed by Akeso and AD Pharmaceuticals (a joint venture with Akeso).
• The new drug marketing application for ebronucimab is based on four pivotal phase 3 studies, including three pivotal studies in patients with primary hypercholesterolemia and mixed hyperlipidemia and one pivotal study in patients with HeFH.
• By promoting a more favorable lipid profile, long-term stable treatment with ebronucimab is expected to achieve greater cardiovascular benefit.